Acute Liver Failure

Quick Answer

Acute Liver Failure (ALF) is the rapid development of hepatic dysfunction (INR ≥1.5) with any degree of hepatic encephalopathy in a patient without pre-existing liver disease, with symptom onset within 26 weeks. The most common cause in the developed world is paracetamol (acetaminophen) toxicity (40-50%), followed by drug-induced liver injury (DILI), viral hepatitis, ischemic hepatitis, Wilson disease, and Budd-Chiari syndrome.[1,2] Complications include cerebral edema (grade III-IV encephalopathy), coagulopathy, sepsis, acute kidney injury, and multi-organ failure. Management focuses on N-acetylcysteine (even for non-paracetamol ALF), cerebral edema prevention (maintain ammonia below 150 µmol/L, consider ICP monitoring for grade III-IV), renal replacement therapy, infection surveillance, and early transplant evaluation using King's College Criteria.[3,4,5] Prognosis without transplantation: paracetamol ALF 50-60% spontaneous survival; non-paracetamol ALF 20-30% spontaneous survival.[6]

---

CICM Exam Focus

Second Part Written Exam

Acute Liver Failure is a high-yield topic for CICM examinations, testing core ICU competencies:

Common SAQ Topics

• "Define acute liver failure and outline the common causes"
• "Describe the King's College Criteria for liver transplantation in ALF"
• "Outline the management of cerebral edema in a patient with ALF"
• "Discuss the role of N-acetylcysteine in non-paracetamol acute liver failure"
• "Compare acute liver failure (ALF) with acute-on-chronic liver failure (ACLF)"
• "Describe the complications of acute liver failure"
• "Outline the indications for renal replacement therapy in ALF"

Viva Scenarios

• 25-year-old with paracetamol overdose, INR 4.5, grade II encephalopathy
• 40-year-old with drug-induced ALF (antibiotics), rising ammonia, worsening confusion
• Managing cerebral edema in grade IV encephalopathy
• Applying King's College Criteria to determine transplant candidacy
• Hepatorenal syndrome type 1 in the context of ALF

---

Key Points

• Definition: INR ≥1.5 + any degree of encephalopathy + symptom onset below 26 weeks + no pre-existing liver disease
• Aetiology: Paracetamol 40-50%, DILI 15-20%, viral hepatitis 10-15%, ischemic 5-10%, indeterminate 15-20%
• Complications: Cerebral edema (20-50% in grade III-IV), infection (50-80%), AKI (40-70%), bleeding (10-30%)
• NAC: Give to ALL ALF patients (paracetamol AND non-paracetamol); improves transplant-free survival in grade I-II non-paracetamol ALF by 22% (52% vs 30%)
• Cerebral Edema: Risk increases exponentially with ammonia greater than 150 µmol/L; consider ICP monitoring for grade III-IV encephalopathy
• King's College Criteria: Most widely used transplant criteria; paracetamol (pH below 7.3 OR INR greater than 6.5 + Cr greater than 300 µmol/L + grade III-IV); non-paracetamol (INR greater than 6.5 OR any 3 of 5 variables)
• Infection: Present in 50-80%; active surveillance cultures every 48-72h; consider prophylactic antibiotics for grade III-IV encephalopathy
• RRT: Indicated for AKI, refractory hyperammonemia (greater than 150-200 µmol/L), severe acidosis (pH below 7.25)
• Prognosis: Overall transplant-free survival: paracetamol ALF 50-60%, non-paracetamol ALF 20-30%

---

Definition and Classification

Definition of Acute Liver Failure

Acute Liver Failure (ALF) is defined by the combination of:[1,2,7]

1. Evidence of acute liver injury (elevated transaminases, jaundice)
2. Coagulopathy: INR ≥1.5 (not correctable with vitamin K)
3. Hepatic encephalopathy: ANY degree (grade I-IV)
4. Symptom duration: below 26 weeks (some use below 24 weeks)
5. Absence of pre-existing liver disease

The term "fulminant hepatic failure" is outdated but still used synonymously with ALF, specifically for cases with encephalopathy onset within 8 weeks of symptom onset.[8]

O'Grady Classification (Time from Jaundice to Encephalopathy)

The O'Grady classification stratifies ALF by the interval from jaundice onset to the development of encephalopathy:[9]

Hyperacute presentations have higher rates of cerebral edema but paradoxically better spontaneous survival due to greater hepatic regenerative capacity.[9,10]

ALF vs Acute-on-Chronic Liver Failure (ACLF)

It is critical to distinguish ALF from ACLF as the pathophysiology, complications, and transplant candidacy differ significantly.[11]

---

Epidemiology

Incidence and Demographics

• Incidence: ALF is rare, affecting approximately 1-6 per million population per year in Western countries.[1,12]
• Age: Bimodal distribution - paracetamol toxicity peaks in young adults (20-40 years); non-paracetamol causes (viral hepatitis, Wilson disease) affect a broader age range.[13]
• Sex: Females are more commonly affected (55-65%), particularly in drug-induced and autoimmune aetiologies.[14]
• Geography: Aetiology varies by region:
  • "Western countries: Paracetamol toxicity predominates (40-50%)"
  • "Asia/Africa: Viral hepatitis (HBV, HEV) more common (40-60%)"
  • "Developing countries: Hepatitis E in pregnancy carries 15-25% mortality[15]"

Mortality and Outcomes

• Overall mortality: 30-40% without transplantation; 20-25% with transplantation available.[16]
• Transplant-free survival:
  • "Paracetamol ALF: 50-60%"
  • "Non-paracetamol ALF: 20-30%"
  • "Indeterminate ALF: 15-25% (worst prognosis)[6,16]"
• Post-transplant survival: 1-year survival 80-85%, 5-year survival 70-75%.[17]
• Prognostic factors: Younger age, hyperacute presentation, paracetamol aetiology, and lower grade encephalopathy at presentation predict better spontaneous survival.[10,18]

---

Aetiology

Common Causes of ALF

Paracetamol (Acetaminophen) Toxicity

Paracetamol is the leading cause of ALF in Western countries (40-50%).[1,19] Hepatotoxicity occurs due to accumulation of the toxic metabolite NAPQI when glutathione stores are depleted.

• Toxic dose: greater than 10 g or greater than 200 mg/kg in adults; greater than 150 mg/kg in children.[20]
• Timing: Transaminases rise at 24-36h, peak at 72-96h; encephalopathy follows at 3-5 days if untreated.
• Clinical triad: Massive transaminase elevation (AST/ALT greater than 3,500 IU/L, often greater than 10,000), acute kidney injury (50-70%), lactic acidosis.
• NAC therapy: Most effective if started within 8 hours of overdose; reduces mortality from 50% to below 5% if given early.[21] Continue NAC until INR below 2.0, improving encephalopathy, and lactate below 2 mmol/L.[22]
• Prognosis: Better spontaneous recovery than non-paracetamol ALF (50-60% transplant-free survival) due to hyperacute presentation.[10]

Drug-Induced Liver Injury (DILI)

DILI accounts for 15-20% of ALF and is the most common cause of ALF in patients greater than 40 years.[23,24]

High-risk medications:

• Antibiotics: Co-amoxiclav, isoniazid, nitrofurantoin, trimethoprim-sulfamethoxazole
• NSAIDs: Diclofenac, ibuprofen (rare but can be fulminant)
• Anticonvulsants: Phenytoin, valproate, carbamazepine
• Herbal supplements: Green tea extract, kava, pyrrolizidine alkaloids

Patterns of injury:

• Hepatocellular: AST/ALT greater than 10x ULN, R-value* greater than 5 (e.g., isoniazid, paracetamol)
• Cholestatic: ALP greater than 2x ULN, R-value below 2 (e.g., co-amoxiclav)
• Mixed: R-value 2-5

*R-value = (ALT ÷ ULN) ÷ (ALP ÷ ULN)

Management: Immediate cessation of offending drug; NAC may improve outcomes even in non-paracetamol DILI.[25]

Wilson Disease

Wilson disease is a rare but critical diagnosis in ALF, as it is universally fatal without emergency liver transplantation.[26,27]

Diagnostic clues:

• Demographics: Young adults (10-40 years)
• Coombs-negative hemolytic anemia: Massive copper release destroys RBCs
• Low alkaline phosphatase: Paradoxically low despite severe liver failure
• ALP:bilirubin ratio below 4: Highly specific (sensitivity/specificity ~94%)[27]
• AST:ALT ratio greater than 2: Reflects mitochondrial enzyme release and hemolysis
• Kayser-Fleischer rings: May be absent in acute presentations

Management:

• Emergency liver transplantation: Only definitive treatment
• Plasmapheresis/plasma exchange: Bridge to transplant; rapidly removes free copper
• Chelation therapy: Ineffective in acute fulminant presentations

---

Pathophysiology

Hepatocyte Necrosis and Apoptosis

ALF results from massive hepatocyte death (necrosis and apoptosis) triggered by toxins (paracetamol), immune-mediated injury (viral hepatitis, autoimmune), or ischemia.[28] The liver's regenerative capacity is overwhelmed, leading to:

1. Loss of synthetic function: Coagulation factors (II, V, VII, IX, X), albumin, cholinesterase
2. Loss of detoxification: Ammonia, bile acids, endotoxins accumulate
3. Metabolic dysfunction: Hypoglycemia (impaired gluconeogenesis), lactic acidosis (impaired lactate clearance)

Hepatic Encephalopathy and Cerebral Edema

Hepatic encephalopathy (HE) in ALF differs fundamentally from HE in cirrhosis. In ALF, the encephalopathy is cytotoxic rather than vasogenic, driven by:[29,30]

1. Hyperammonemia: Ammonia crosses the blood-brain barrier → astrocytes convert to glutamine → osmotic swelling → cerebral edema
2. Inflammatory cytokines: TNF-α, IL-1β, IL-6 increase blood-brain barrier permeability
3. Oxidative stress: Reactive oxygen species (ROS) cause mitochondrial dysfunction in astrocytes
4. Impaired cerebral autoregulation: Loss of cerebral perfusion pressure (CPP) regulation

Risk factors for cerebral edema:[31]

• Grade III-IV encephalopathy (risk 25-50%)
• Ammonia greater than 150 µmol/L (exponential risk increase)
• Acute kidney injury
• Hyperacute presentation (paracetamol, hepatitis A)
• Younger age (below 40 years)
• Vasopressor requirement

Clinical features of cerebral edema:

• Worsening confusion, agitation, decerebrate posturing
• Hypertension with bradycardia (Cushing reflex)
• Pupillary abnormalities (sluggish, dilated)
• Seizures (10-30%)

Coagulopathy

ALF causes a complex coagulopathy with features of both bleeding and thrombosis:[32]

Pro-hemorrhagic factors:

• Reduced synthesis of clotting factors (II, V, VII, IX, X, fibrinogen)
• Thrombocytopenia (50-70% of patients; platelet count 50-100 × 10⁹/L)
• Dysfibrinogenemia (abnormal fibrinogen function)

Pro-thrombotic factors:

• Reduced synthesis of anticoagulants (protein C, protein S, antithrombin)
• Elevated factor VIII and von Willebrand factor (endothelial release)
• "Rebalanced hemostasis": Despite elevated INR, thromboelastography (TEG/ROTEM) often shows normal or even hypercoagulable state

Clinical significance:

• INR is a prognostic marker, NOT a guide to bleeding risk in ALF
• Actual bleeding complications occur in only 10-30% of ALF patients despite INR greater than 2-3[33]
• Thrombotic complications (portal vein thrombosis, pulmonary embolism) occur in 5-10%[32]

Multi-Organ Failure

ALF triggers a systemic inflammatory response syndrome (SIRS) leading to multi-organ dysfunction:[34]

Renal failure (40-70%):

• Type 1 hepatorenal syndrome (HRS-1): Pre-renal (splanchnic vasodilation, reduced effective circulating volume)
• Acute tubular necrosis (ATN): Toxin-mediated (paracetamol), ischemic, sepsis-related

Cardiovascular dysfunction:

• Hyperdynamic circulation: High cardiac output, low systemic vascular resistance (SVR)
• Vasopressor requirement (30-50%): Noradrenaline first-line

Pulmonary complications:

• ARDS (5-15%)
• Hepatopulmonary syndrome (rare in ALF)

Infection/Sepsis (50-80%):

• Bacterial infections: 50-60% (Staphylococcus aureus, E. coli, Klebsiella)
• Fungal infections: 20-30% (Candida albicans)
• Mechanisms: Impaired Kupffer cell function, reduced complement, neutrophil dysfunction

---

Clinical Presentation

Hepatic Encephalopathy (West Haven Grading)

Hepatic encephalopathy is mandatory for the diagnosis of ALF. The West Haven criteria grade severity:[35]

Clinical pearls:

• Asterixis ("flapping tremor") is present in grades I-III, absent in grade IV
• Avoid sedation if possible - masks progression and prevents clinical monitoring
• Serial GCS and neurological examination every 2-4 hours

Jaundice and Hepatomegaly

• Jaundice: Present in 80-90% of ALF; bilirubin may be disproportionately low in hyperacute presentations (paracetamol)
• Hepatomegaly: Variable; liver may be small and shrunken in subacute presentations
• Right upper quadrant pain: Suggests Budd-Chiari syndrome, ischemic hepatitis, or acute hepatitis

Signs of Chronic Liver Disease

By definition, ALF occurs in patients without pre-existing liver disease. Presence of the following suggests ACLF, not ALF:

• Spider nevi, palmar erythema
• Gynecomastia, testicular atrophy
• Caput medusae (collateral circulation)
• Splenomegaly (portal hypertension)

---

Investigations

Initial Laboratory Studies

Aetiology Workup

All ALF patients require a comprehensive aetiology screen:[2,36]

Imaging

• Ultrasound abdomen: First-line; assess liver echogenicity, bile ducts, hepatic vessels (Doppler for Budd-Chiari), ascites, splenomegaly
• CT/MRI abdomen: If Budd-Chiari, malignancy, or ischemic hepatitis suspected
• CT head (non-contrast): If cerebral edema suspected (midline shift, effacement of sulci, loss of grey-white differentiation); avoid in coagulopathy unless corrected

Prognostic Markers

King's College Criteria (most widely used):[37]

Paracetamol ALF:

• Arterial pH below 7.3 (after resuscitation) OR
• All three of:
  • INR greater than 6.5 (PT greater than 100 seconds)
  • Creatinine greater than 300 µmol/L (greater than 3.4 mg/dL)
  • Grade III-IV encephalopathy

Non-paracetamol ALF:

• INR greater than 6.5 (PT greater than 100 seconds) OR
• Any three of the following five:
  • Age below 10 or greater than 40 years
  • "Aetiology: Non-A, non-B hepatitis, halothane, idiosyncratic drug reaction"
  • Duration jaundice to encephalopathy greater than 7 days
  • INR greater than 3.5 (PT greater than 50 seconds)
  • Bilirubin greater than 300 µmol/L (greater than 17.5 mg/dL)

Sensitivity/Specificity: King's College Criteria have sensitivity 58-69% and specificity 82-95% for predicting death without transplantation.[37,38]

Other prognostic scores:

• MELD score: Useful for chronic liver disease; less validated in ALF but increasingly used in some centres
• ALFSG Prognostic Index: Uses admission coma grade, INR, bilirubin, phosphate; validated in US ALF Study Group cohort[39]
• Lactate greater than 3.5 mmol/L at 4-12 hours after resuscitation: Predicts poor outcome independent of King's College Criteria[40]

---

Management

General Principles

1. Early ICU admission: All ALF patients require ICU-level care
2. Transplant centre referral: Discuss with liver transplant unit early (ideally within 24h of diagnosis)
3. Multidisciplinary approach: Hepatology, ICU, transplant surgery, pharmacy, nephrology
4. Avoid hepatotoxic drugs: NSAIDs, sedatives (if possible), nephrotoxic agents
5. Minimise sedation: Use only if essential (intubation, agitation with risk of self-harm); propofol preferred over benzodiazepines

Specific Therapies

N-Acetylcysteine (NAC)

NAC is the antidote for paracetamol poisoning and has additional benefits in non-paracetamol ALF.[21,25]

Paracetamol ALF:

• Indications: All patients with paracetamol overdose and hepatotoxicity (transaminases greater than 1,000 IU/L or INR greater than 1.5)
• Regimen (UK protocol):
  • "Loading: 150 mg/kg IV over 1 hour"
  • "Second infusion: 50 mg/kg over 4 hours"
  • "Maintenance: 100 mg/kg over 16 hours"
  • Continue until INR below 2.0, encephalopathy improving, and lactate below 2 mmol/L (may require 48-72h or longer)[22]
• Timing: Most effective if started within 8 hours; still beneficial up to 24-48 hours
• Mechanism: Replenishes glutathione; scavenges NAPQI; improves hepatic and systemic oxygen delivery

Non-paracetamol ALF:[25,41]

• Evidence: Lee et al. (2009) RCT (PMID: 19828176) showed NAC improved transplant-free survival in early-stage (grade I-II encephalopathy) non-paracetamol ALF:
  • "NAC group: 52% transplant-free survival"
  • "Placebo group: 30% transplant-free survival"
  • Benefit lost in grade III-IV encephalopathy (NAC 9% vs placebo 22%; not statistically significant)
• Regimen: Same as paracetamol protocol; continue for 3-5 days or until transplant/clinical improvement
• Proposed mechanisms: Antioxidant, anti-inflammatory, improves microvascular perfusion

Adverse effects: Anaphylactoid reactions (10-20%): flushing, urticaria, bronchospasm; usually mild and resolve with slowing infusion rate; true anaphylaxis is rare (below 1%).

Cerebral Edema and Intracranial Hypertension

Cerebral edema is the leading cause of death in ALF (20-25% of deaths).[31,42]

Prevention:

1. Ammonia control:

   • Target ammonia below 100-150 µmol/L
   • CRRT (continuous renal replacement therapy): Most effective for ammonia clearance; high-volume CRRT for refractory hyperammonemia (greater than 150-200 µmol/L)[43]
   • Therapeutic plasma exchange (TPE): Removes ammonia, inflammatory cytokines, and replaces coagulation factors; may improve transplant-free survival[44]
   • Lactulose: Controversial; not recommended as primary therapy (may cause bowel distension, complicating transplant surgery); LOLA (L-ornithine L-aspartate) has limited evidence[45]

2. Head elevation: 30 degrees

3. Avoid hyperthermia: Target normothermia (36-37°C); pyrexia increases cerebral metabolic demand

4. Glycemic control: Maintain glucose 5-10 mmol/L; hypoglycemia increases cerebral edema risk

5. Sedation minimization: Propofol preferred over benzodiazepines if sedation required

6. Avoid excessive fluid resuscitation: Target euvolemia; hyponatremia (below 135 mmol/L) worsens cerebral edema

ICP Monitoring:[46,47]

• Indications: Grade III-IV encephalopathy, especially if awaiting transplantation; ammonia greater than 150-200 µmol/L
• Contraindications: Severe coagulopathy (INR greater than 3.0, platelets below 50 × 10⁹/L) unless corrected; active bleeding
• Type: Intraparenchymal microtransducer preferred (epidural monitors unreliable)
• Targets:
  • ICP below 20-25 mmHg
  • Cerebral perfusion pressure (CPP) greater than 50-60 mmHg (CPP = MAP - ICP)
• Risks: Intracranial hemorrhage (5-10% risk)

Treatment of elevated ICP:[48]

1. Mannitol 20%: 0.5-1 g/kg IV bolus over 15-20 minutes; repeat PRN; maintain serum osmolality 310-320 mOsmol/kg; avoid if oliguric or serum osmolality greater than 320
2. Hypertonic saline (3% or 5%): 150-250 mL bolus; may be superior to mannitol; safe in renal failure
3. Moderate hypothermia (32-34°C): Reduces cerebral metabolic rate; evidence limited to case series; risk of infection, coagulopathy; not routinely recommended[49]
4. Thiopental/pentobarbital coma: Last resort; profound immunosuppression and hemodynamic instability

Contraindications to transplantation (cerebral edema):

• Sustained ICP greater than 50 mmHg
• CPP below 40 mmHg despite maximal therapy
• Fixed dilated pupils (suggests brainstem herniation)

Renal Replacement Therapy (RRT)

Indications:[50]

• Acute kidney injury (AKI) with:
  • Oliguria/anuria despite resuscitation
  • Volume overload
  • Severe acidosis (pH below 7.25)
  • Electrolyte abnormalities (hyperkalemia greater than 6.5 mmol/L)
• Hyperammonemia (ammonia greater than 150-200 µmol/L) refractory to medical management
• Type 1 hepatorenal syndrome (HRS-1)

Modality:

• Continuous RRT (CRRT) preferred: Better hemodynamic stability, superior ammonia clearance, avoids cerebral edema exacerbation from rapid fluid shifts
• Intermittent hemodialysis (IHD): May be used if CRRT unavailable; risk of hypotension, worsening cerebral perfusion

Hepatorenal syndrome (HRS):

• HRS-1: Rapid progression (doubling of creatinine to greater than 221 µmol/L or 50% reduction in GFR within 2 weeks)
• Management: Terlipressin + albumin may improve renal function as bridge to transplantation; evidence limited in ALF (most studies in cirrhosis)[51]

Infection and Sepsis

Infection occurs in 50-80% of ALF patients and is a major cause of exclusion from transplantation.[52,53]

Surveillance:

• Blood cultures, urine culture, sputum culture (if intubated): At admission, then every 48-72 hours
• Low threshold for additional cultures if clinical deterioration (fever, rising WCC, worsening encephalopathy)

Prophylactic antibiotics:

• Controversial: Guidelines (AASLD, EASL) do not recommend universal prophylaxis[2,54]
• Consider for:
  • Grade III-IV encephalopathy
  • Vasopressor requirement
  • Renal failure on RRT
  • Awaiting urgent transplantation
• Regimen: Broad-spectrum (e.g., piperacillin-tazobactam 4.5 g IV 8-hourly); add antifungal (fluconazole 400 mg daily or echinocandin) if high risk

Empirical therapy:

• Start immediately if signs of SIRS/sepsis (after cultures drawn)
• Broad-spectrum antibiotics covering Gram-positive and Gram-negative bacteria
• Consider fungal coverage if prolonged ICU stay, broad-spectrum antibiotic use, or deterioration despite antibacterial therapy

Coagulopathy and Bleeding

Key principles:[32,33]

1. Do NOT correct INR routinely: INR is a prognostic marker; routine correction with FFP/PCC masks ability to assess liver function and transplant criteria
2. Correct coagulopathy ONLY for:
   • Active bleeding
   • Invasive procedures (ICP monitor insertion, central line, liver biopsy)
3. Products:
   • Fresh frozen plasma (FFP): 10-15 mL/kg; risk of volume overload
   • Cryoprecipitate: If fibrinogen below 1.5 g/L
   • Platelets: If platelets below 50 × 10⁹/L and bleeding or procedure
   • Prothrombin complex concentrate (PCC): Use cautiously; risk of thrombosis in "rebalanced" hemostasis
4. Proton pump inhibitors (PPIs): Pantoprazole 40 mg IV daily for stress ulcer prophylaxis
5. Avoid: Aspirin, NSAIDs, intramuscular injections

Metabolic Support

Hypoglycemia:

• Monitoring: Capillary glucose every 2-4 hours
• Treatment: IV dextrose 10-20% infusion to maintain glucose 5-10 mmol/L; avoid hypoglycemia (below 3 mmol/L)

Nutrition:

• Enteral nutrition preferred: Start within 24-48 hours if hemodynamically stable; standard polymeric feed (1-1.2 kcal/mL)
• Protein restriction NOT recommended: Adequate protein (1.2-1.5 g/kg/day) essential for hepatic regeneration; myth that protein worsens encephalopathy in ALF[55]
• Parenteral nutrition: If enteral feeding not tolerated; risk of infection

Electrolytes:

• Sodium: Maintain 140-145 mmol/L; avoid hyponatremia (worsens cerebral edema) and rapid correction (risk of osmotic demyelination)
• Phosphate: Monitor closely; hyperphosphatemia on day 2-3 in paracetamol ALF predicts poor outcome; hypophosphatemia may occur with RRT
• Potassium: Correct hypokalemia (below 3.5 mmol/L); monitor for hyperkalemia in AKI

Liver Transplantation

Emergency liver transplantation is the definitive treatment for ALF with poor predicted spontaneous survival.[56,57]

Indications (King's College Criteria):[37]

• Paracetamol ALF: pH below 7.3 OR (INR greater than 6.5 + Cr greater than 300 µmol/L + grade III-IV encephalopathy)
• Non-paracetamol ALF: INR greater than 6.5 OR any 3 of 5 criteria (age, aetiology, jaundice-to-encephalopathy interval, INR, bilirubin)

Contraindications:

• Absolute: Multi-organ failure with no prospect of recovery, irreversible brain injury (fixed dilated pupils, cerebral herniation), severe cardiopulmonary disease, active malignancy, active substance abuse
• Relative: Age greater than 70 years, HIV (CD4 below 100), uncontrolled sepsis (relative)

Listing:

• UNOS Status 1A (USA): Highest priority for acute liver failure patients
• Super-urgent (Euroransplant, UK): Top of waiting list

Post-transplant survival: 1-year survival 80-85%, 5-year survival 70-75%.[17]

Living donor liver transplantation (LDLT): Increasingly used for ALF; allows transplantation without waiting for deceased donor; comparable outcomes to deceased donor transplantation.[58]

---

Complications

Cerebral Edema and Intracranial Hypertension

• Incidence: 20-50% in grade III-IV encephalopathy; higher in hyperacute presentations
• Mortality: Leading cause of death (20-25% of ALF deaths)
• Mechanism: Ammonia-induced astrocyte swelling, cytokine-mediated BBB disruption, oxidative stress
• See detailed management above

Infection and Sepsis

• Incidence: 50-80% bacterial infections, 20-30% fungal infections
• Pathogens: Staphylococcus aureus, E. coli, Klebsiella, Candida albicans
• Impact: Major cause of exclusion from transplantation; worsens encephalopathy
• See detailed management above

Acute Kidney Injury

• Incidence: 40-70% of ALF patients
• Types:
  • "Hepatorenal syndrome type 1 (HRS-1): 30-40%"
  • "Acute tubular necrosis (ATN): 40-50%"
  • "Direct toxin effect (paracetamol): 50-70% of paracetamol ALF"
• Prognosis: AKI requiring RRT predicts worse outcome (increased mortality, longer hospital stay)

Cardiovascular Dysfunction

• Hyperdynamic circulation: High cardiac output, low SVR (similar to septic shock)
• Vasopressor requirement: 30-50%; noradrenaline first-line
• Arrhythmias: Atrial fibrillation, ventricular tachycardia (rare)

Pulmonary Complications

• ARDS: 5-15%; high mortality (greater than 50%)
• Pulmonary hemorrhage: Rare (below 2%); associated with severe coagulopathy
• Hepatopulmonary syndrome: Rare in ALF (more common in cirrhosis)

Haematological Complications

• Thrombocytopenia: 50-70%; platelet count 50-100 × 10⁹/L
• Hemolysis: Coombs-negative hemolytic anemia in Wilson disease
• Bleeding: 10-30% despite marked coagulopathy
• Thrombosis: Portal vein thrombosis, pulmonary embolism (5-10%)

---

Prognosis

Transplant-Free Survival

Prognostic Factors

Favourable:[10,18]

• Younger age (below 40 years)
• Hyperacute presentation (paracetamol, hepatitis A)
• Lower grade encephalopathy at presentation (grade I-II)
• Paracetamol aetiology (vs non-paracetamol)
• Lower bilirubin (below 200 µmol/L)
• Absence of AKI

Unfavourable:[59]

• Subacute presentation (greater than 28 days jaundice to encephalopathy)
• Indeterminate aetiology
• Grade IV encephalopathy
• Lactate greater than 3.5 mmol/L at 4-12 hours post-resuscitation
• Phosphate greater than 1.2 mmol/L on day 2-3 (paracetamol ALF)
• AKI requiring RRT
• Vasopressor requirement

Long-Term Outcomes Post-Transplantation

• 1-year survival: 80-85%
• 5-year survival: 70-75%
• 10-year survival: 60-65%
• Quality of life: Comparable to general population in successful transplant recipients
• Recurrence: Autoimmune hepatitis and hepatitis B may recur post-transplant (requires lifelong immunosuppression and antivirals)

---

CICM SAQ Practice

SAQ 1: Definition and Aetiology

Question: Define acute liver failure and outline the five most common causes in developed countries.

Model Answer:

Definition: Acute Liver Failure (ALF) is defined by:

1. Evidence of acute liver injury (elevated transaminases, jaundice)
2. Coagulopathy: INR ≥1.5
3. Hepatic encephalopathy: Any degree (grade I-IV)
4. Symptom duration below 26 weeks
5. Absence of pre-existing chronic liver disease

Five Most Common Causes:

1. Paracetamol (Acetaminophen) Toxicity (40-50%)

   • Intentional overdose (greater than 10 g or greater than 200 mg/kg)
   • Massive transaminase elevation (AST/ALT greater than 10,000 IU/L)
   • N-acetylcysteine is antidote; most effective within 8 hours

2. Drug-Induced Liver Injury (DILI) (15-20%)

   • Antibiotics: Co-amoxiclav, isoniazid, nitrofurantoin
   • NSAIDs: Diclofenac
   • Anticonvulsants: Phenytoin, valproate
   • Immediate cessation of offending drug

3. Viral Hepatitis (10-15%)

   • Hepatitis A (rare cause of ALF, 0.1-0.35%)
   • Hepatitis B (10-15% in endemic areas)
   • Hepatitis E (pregnancy)
   • CMV, EBV, HSV (immunocompromised)

4. Ischemic Hepatitis (Shock Liver) (5-10%)

   • Severe hypotension, cardiac arrest, cardiogenic shock
   • Transaminases greater than 5,000-10,000 IU/L
   • Rapid improvement with restoration of perfusion

5. Indeterminate (15-20%)

   • No cause identified despite full workup
   • Worst prognosis (spontaneous survival 15-25%)

Other important causes: Wilson disease (2-5%), Budd-Chiari syndrome (1-3%), autoimmune hepatitis (5-10%)

---

SAQ 2: King's College Criteria

Question: Outline the King's College Criteria for liver transplantation in acute liver failure.

Model Answer:

The King's College Criteria identify ALF patients unlikely to survive without emergency liver transplantation.

Paracetamol ALF:

Transplant indicated if:

• Arterial pH below 7.3 (after adequate resuscitation) OR
• All three of:
  • INR greater than 6.5 (PT greater than 100 seconds)
  • Serum creatinine greater than 300 µmol/L (greater than 3.4 mg/dL)
  • Grade III-IV hepatic encephalopathy

Non-Paracetamol ALF:

Transplant indicated if:

• INR greater than 6.5 (PT greater than 100 seconds) OR
• Any three of the following five criteria:
  1. Age below 10 or greater than 40 years
  2. Aetiology: Non-A non-B hepatitis, halothane, or idiosyncratic drug reaction
  3. Duration from jaundice to encephalopathy greater than 7 days
  4. INR greater than 3.5 (PT greater than 50 seconds)
  5. Bilirubin greater than 300 µmol/L (greater than 17.5 mg/dL)

Performance Characteristics:

• Sensitivity: 58-69% (misses some patients who will die)
• Specificity: 82-95% (correctly identifies those who will survive)

Additional Prognostic Markers:

• Lactate greater than 3.5 mmol/L at 4-12 hours post-resuscitation (independent predictor of poor outcome)
• Phosphate greater than 1.2 mmol/L on day 2-3 (paracetamol ALF)
• MELD score (increasingly used in some centres)

---

SAQ 3: Cerebral Edema Management

Question: Describe the management of cerebral edema in a patient with acute liver failure and grade IV hepatic encephalopathy.

Model Answer:

Prevention:

1. Ammonia Control:

   • Target ammonia below 100-150 µmol/L
   • CRRT: Most effective for ammonia clearance; high-volume CRRT for levels greater than 150-200 µmol/L
   • Therapeutic plasma exchange (TPE): Removes ammonia, inflammatory cytokines
   • Lactulose NOT recommended as primary therapy in ALF (bowel distension)

2. General Measures:

   • Head elevation 30 degrees
   • Normothermia (36-37°C); avoid pyrexia
   • Euglycemia (glucose 5-10 mmol/L)
   • Euvolemia; avoid hyponatremia (below 135 mmol/L)
   • Minimal sedation (propofol preferred if required)

ICP Monitoring:

Indications:

• Grade III-IV encephalopathy
• Ammonia greater than 150-200 µmol/L
• Awaiting liver transplantation

Type: Intraparenchymal microtransducer (epidural unreliable)

Targets:

• ICP below 20-25 mmHg
• CPP (MAP - ICP) greater than 50-60 mmHg

Contraindications: Severe uncorrected coagulopathy (INR greater than 3, platelets below 50 × 10⁹/L); active bleeding

Treatment of Elevated ICP:

1. Mannitol 20%: 0.5-1 g/kg IV bolus over 15-20 minutes

   • Repeat PRN
   • Maintain serum osmolality 310-320 mOsmol/kg
   • Avoid if oliguric or osmolality greater than 320

2. Hypertonic saline (3% or 5%): 150-250 mL bolus

   • May be superior to mannitol
   • Safe in renal failure

3. Moderate hypothermia (32-34°C): Reduces cerebral metabolic rate

   • Limited evidence; risk of infection, coagulopathy
   • Not routinely recommended

4. Thiopental coma: Last resort; profound immunosuppression

Contraindications to Transplantation:

• Sustained ICP greater than 50 mmHg
• CPP below 40 mmHg despite maximal therapy
• Fixed dilated pupils (brainstem herniation)

---

SAQ 4: N-Acetylcysteine in Non-Paracetamol ALF

Question: Discuss the role of N-acetylcysteine (NAC) in non-paracetamol acute liver failure.

Model Answer:

Evidence:

The landmark Lee et al. (2009) randomized controlled trial (PMID: 19828176) investigated NAC in non-paracetamol ALF:

• Design: Prospective, double-blind, placebo-controlled, multicenter
• Participants: 173 patients with non-paracetamol ALF (DILI, autoimmune, hepatitis B, indeterminate)

Key Findings:

1. Primary Outcome (Transplant-Free Survival at 3 weeks):

   • Overall: No significant difference (NAC 40% vs placebo 27%, p=0.092)

2. Subgroup Analysis by Encephalopathy Grade:

   • Grade I-II (early stage): NAC significantly improved transplant-free survival
     • NAC: 52%
     • Placebo: 30%
     • NNT = 4.5
   • Grade III-IV (advanced stage): No benefit
     • NAC: 9%
     • Placebo: 22%
     • (Not statistically significant)

3. Overall Survival (including transplant): No significant difference (70% NAC vs 66% placebo)

Proposed Mechanisms:

• Antioxidant effects (scavenges reactive oxygen species)
• Anti-inflammatory (reduces cytokine release)
• Improves hepatic and systemic microvascular perfusion
• Enhances oxygen delivery to tissues

Current Recommendations:

AASLD/EASL Guidelines: Consider NAC for all non-paracetamol ALF, particularly:

• Grade I-II encephalopathy (strongest evidence)
• Early in disease course
• Drug-induced liver injury

Dosing:

• Same as paracetamol protocol:
  • "Loading: 150 mg/kg IV over 1h"
  • "Second: 50 mg/kg over 4h"
  • "Maintenance: 100 mg/kg over 16h"
• Continue for 3-5 days or until transplantation/clinical improvement

Adverse Effects:

• Anaphylactoid reactions: 10-20% (flushing, urticaria, bronchospasm)
• Usually mild; slow infusion rate
• True anaphylaxis rare (below 1%)

Limitations:

• No benefit in advanced encephalopathy (grade III-IV)
• Does not reduce need for transplantation
• Requires early administration for maximum benefit

---

CICM Viva Practice

Viva 1: Paracetamol Overdose with ALF

Scenario: You are the ICU consultant. A 25-year-old female is admitted with a paracetamol overdose (25 g ingested 36 hours ago). She is confused, jaundiced, and has an INR of 4.5. Discuss your management.

Opening Gambit: "This is acute liver failure secondary to paracetamol toxicity. The patient has taken a potentially fatal overdose 36 hours ago and now has evidence of hepatic dysfunction (jaundice, INR 4.5) and encephalopathy (confusion). My immediate priorities are: (1) assess and stabilize the patient (ABCs), (2) start N-acetylcysteine immediately, (3) grade the hepatic encephalopathy, (4) perform a full aetiology and complication screen, and (5) contact the liver transplant unit for early discussion."

Anticipated Questions:

Q1: What defines acute liver failure? A: ALF requires five criteria: (1) acute liver injury, (2) INR ≥1.5, (3) any degree of hepatic encephalopathy, (4) symptom onset below 26 weeks, and (5) no pre-existing chronic liver disease. This patient meets all criteria.

Q2: How would you grade the hepatic encephalopathy? A: Using the West Haven criteria:

• Grade I: Mild confusion, sleep disturbance, asterixis
• Grade II: Lethargy, disorientation to time/place, marked asterixis
• Grade III: Somnolence, responsive to verbal stimuli, hyperreflexia
• Grade IV: Coma (IVa responsive to pain, IVb unresponsive)

In this patient, "confused" suggests grade I-II. I would perform a detailed neurological examination including GCS, orientation, asterixis, and reflexes. Serial assessments every 2-4 hours are essential to detect progression.

Q3: Why is NAC indicated 36 hours post-overdose? A: NAC is the antidote for paracetamol poisoning. While most effective if started within 8 hours, it remains beneficial up to 24-48 hours and beyond in established ALF. Mechanisms include: (1) replenishing glutathione to detoxify NAPQI, (2) antioxidant effects, (3) improving hepatic microvascular perfusion, and (4) enhancing systemic oxygen delivery. I would start NAC immediately using the UK protocol (150 mg/kg loading over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h), and continue until INR below 2.0, encephalopathy improves, and lactate below 2 mmol/L.

Q4: What investigations would you order? A: Immediate:

• FBC (infection, thrombocytopenia)
• Coagulation (INR, PT, APTT, fibrinogen)
• Liver function tests (AST, ALT, bilirubin, ALP, albumin)
• Renal function (urea, creatinine - hepatorenal syndrome in 50-70% of paracetamol ALF)
• Glucose (4-hourly monitoring - risk of hypoglycemia)
• Arterial blood gas (pH below 7.3 is a King's College transplant criterion)
• Lactate (greater than 3.5 mmol/L at 4-12h predicts poor outcome)
• Ammonia (risk of cerebral edema if greater than 150 µmol/L)
• Phosphate (hyperphosphatemia on day 2-3 predicts poor outcome)
• Paracetamol level (may be undetectable at 36h)

Imaging: Ultrasound abdomen (liver echogenicity, exclude Budd-Chiari, ascites)

Q5: When would you apply King's College Criteria? A: King's College Criteria identify patients unlikely to survive without emergency liver transplantation. For paracetamol ALF, transplant is indicated if:

• Arterial pH below 7.3 (after resuscitation) OR
• All three of: INR greater than 6.5, creatinine greater than 300 µmol/L, and grade III-IV encephalopathy

This patient currently has INR 4.5 and grade I-II encephalopathy. I would contact the transplant unit early for discussion, repeat arterial blood gas after resuscitation to assess pH, monitor creatinine closely, and reassess encephalopathy grade every 2-4 hours. If she meets criteria, she requires emergency listing for transplantation (UNOS Status 1A).

Q6: What are the complications of paracetamol-induced ALF? A: Major complications include:

1. Cerebral edema (20-50% in grade III-IV): Ammonia-induced astrocyte swelling
2. Acute kidney injury (50-70%): Direct tubular toxicity from paracetamol metabolites
3. Infection/sepsis (50-80%): Bacterial and fungal
4. Coagulopathy: INR elevation, thrombocytopenia, bleeding (10-30%)
5. Metabolic: Hypoglycemia, lactic acidosis, electrolyte disturbances
6. Cardiovascular: Hyperdynamic circulation, vasopressor requirement (30-50%)

Q7: If the ammonia rises to 180 µmol/L, what would you do? A: Ammonia greater than 150 µmol/L indicates high risk of cerebral edema. My management would include:

1. CRRT: Most effective for ammonia clearance; high-volume CRRT for levels greater than 150-200 µmol/L
2. General measures: Head elevation 30 degrees, normothermia, euglycemia, avoid hyponatremia, minimal sedation
3. Consider ICP monitoring if grade III-IV encephalopathy develops (intraparenchymal transducer; targets ICP below 20-25 mmHg, CPP greater than 50-60 mmHg)
4. Therapeutic plasma exchange: Removes ammonia and inflammatory cytokines; may improve transplant-free survival
5. Avoid lactulose (not recommended as primary therapy in ALF; causes bowel distension)

---

Viva 2: Wilson Disease Presenting as ALF

Scenario: A 22-year-old male presents with jaundice, confusion (grade II encephalopathy), and dark urine. Blood tests show: INR 3.8, bilirubin 350 µmol/L, AST 980 IU/L, ALT 420 IU/L, ALP 95 IU/L, hemoglobin 75 g/L. What is your differential diagnosis and management?

Opening Gambit: "This is acute liver failure in a young male with grade II encephalopathy. The key diagnostic clue is the combination of severe jaundice, anemia, and paradoxically low alkaline phosphatase. This pattern, along with AST:ALT ratio greater than 2, strongly suggests Wilson disease presenting as fulminant hepatic failure with Coombs-negative hemolytic anemia. This is a medical emergency requiring immediate contact with the liver transplant unit, as Wilson disease ALF is universally fatal without emergency transplantation."

Anticipated Questions:

Q1: Why does the low ALP suggest Wilson disease? A: Wilson disease causes massive release of copper into the bloodstream, which has several effects:

1. Paradoxically low alkaline phosphatase: Despite severe liver failure, ALP is often normal or low (95 IU/L in this case). Copper may interfere with the zinc cofactor required for ALP activity.
2. ALP:bilirubin ratio below 4: This ratio (ALP 95 ÷ bilirubin 350 = 0.27) is highly specific for Wilson disease (sensitivity/specificity ~94%).
3. AST:ALT ratio greater than 2 (980÷420 = 2.3): Reflects mitochondrial enzyme release and contribution from hemolysis.

Q2: What investigations would confirm Wilson disease? A:

1. Serum ceruloplasmin: below 20 mg/dL is suggestive (but may be normal as it is an acute-phase reactant)
2. 24-hour urinary copper: Markedly elevated (often greater than 1,000 µg/24h; normal below 40 µg/24h)
3. Serum copper: Massively elevated (greater than 200 µg/dL)
4. Coombs test: Negative hemolytic anemia (confirms copper-induced RBC destruction, not autoimmune)
5. Slit-lamp examination: Kayser-Fleischer rings (may be absent in acute presentations)
6. Liver biopsy: Elevated hepatic copper content (greater than 250 µg/g dry weight); often not feasible due to coagulopathy
7. Genetic testing: ATP7B gene mutations (confirmatory but results take weeks)

Q3: Why is the patient anemic? A: The anemia (hemoglobin 75 g/L) is due to Coombs-negative hemolytic anemia, a hallmark of fulminant Wilson disease. The massive release of free copper into the bloodstream causes oxidative damage to red blood cell membranes, leading to severe hemolysis. The Coombs test is negative, distinguishing this from autoimmune hemolytic anemia. Additional evidence of hemolysis includes: elevated LDH, elevated unconjugated bilirubin, reduced haptoglobin, and reticulocytosis.

Q4: What is the definitive management? A: Emergency liver transplantation is the ONLY definitive treatment for fulminant Wilson disease. Without transplantation, mortality is essentially 100%.

Bridge to transplantation:

1. Plasmapheresis/Therapeutic plasma exchange (TPE): Rapidly removes free copper, reduces hemolysis, improves renal function; may stabilize patient for 24-48 hours
2. Continuous RRT: Manages acute kidney injury (common in Wilson ALF due to copper-induced tubular damage and hemoglobinuria)
3. Blood transfusion: For severe anemia (target hemoglobin greater than 70-80 g/L)
4. Supportive ICU care: Encephalopathy management, infection surveillance, hemodynamic support

Q5: Would you use chelation therapy? A: No. Standard copper chelators (D-penicillamine, trientine) are:

1. Too slow: Take weeks to months to reduce copper burden
2. Potentially harmful: May initially worsen copper release and hemolysis
3. Ineffective in fulminant disease: Cannot reverse established liver failure

Chelation is reserved for chronic Wilson disease management post-transplantation to prevent copper accumulation in the transplanted liver.

Q6: What scoring system predicts survival? A: The Revised Wilson Disease Index (Nazer Score) predicts mortality and need for transplantation:

Variables:

• Bilirubin (mg/dL)
• AST (IU/L)
• INR
• Albumin (g/dL)
• WBC (× 10⁹/L)

A score ≥11 indicates very high risk of death without emergency transplantation. Alternatively, the presence of:

• ALP:bilirubin ratio below 4
• AST:ALT greater than 2
• Coombs-negative hemolysis strongly suggests need for emergency listing.

Q7: What other prognostic markers would you monitor? A: Beyond King's College Criteria, I would monitor:

1. Lactate: greater than 3.5 mmol/L at 4-12 hours post-resuscitation predicts poor outcome independent of King's College Criteria
2. Phosphate: Hyperphosphatemia (greater than 1.2 mmol/L) on day 2-3 is a poor prognostic sign in paracetamol ALF
3. Factor V level: below 20% indicates severe synthetic dysfunction
4. Ammonia trend: Rising levels (greater than 150-200 µmol/L) predict cerebral edema
5. Renal function: Rising creatinine (part of King's College Criteria for paracetamol)
6. Encephalopathy grade progression: Worsening grade despite treatment suggests poor prognosis

---

Viva 3: Drug-Induced Liver Injury with Grade III Encephalopathy

Scenario: A 55-year-old female on rifampicin and isoniazid for TB (started 6 weeks ago) presents with jaundice, confusion, and asterixis. Investigations: INR 4.2, bilirubin 420 µmol/L, AST 2,800 IU/L, ALT 3,200 IU/L, ammonia 185 µmol/L, creatinine 145 µmol/L. She is GCS 12 (E3V4M5), combative, with hyperreflexia and asterixis. Discuss your management.

Opening Gambit: "This is acute liver failure secondary to drug-induced liver injury (DILI) from anti-tuberculous medications, most likely isoniazid. The patient has grade III hepatic encephalopathy (GCS 12, confusion, asterixis) with markedly elevated ammonia (185 µmol/L), placing her at high risk of cerebral edema and intracranial hypertension. My immediate priorities are: (1) airway protection and ICU admission, (2) immediately stop all hepatotoxic medications, (3) start N-acetylcysteine, (4) initiate cerebral edema prevention strategies including CRRT for hyperammonemia, (5) consider ICP monitoring, and (6) urgent transplant centre discussion as she is a potential candidate for emergency liver transplantation."

Anticipated Questions:

Q1: Why intubate a patient with grade III encephalopathy? A: Grade III encephalopathy (GCS 8-12, somnolent but rousable) has several indications for intubation:

1. Airway protection: Reduced conscious level with risk of aspiration
2. Agitation management: This patient is "combative"

• may require sedation for safety and to facilitate procedures

3. Bridge to grade IV: High risk of progression to grade IV (coma) given elevated ammonia (185 µmol/L)
4. ICP monitoring: If considering ICP monitor insertion, intubation provides controlled ventilation and cerebral protection
5. Controlled hyperventilation: Target PaCO2 35-40 mmHg (mild hypocarbia may reduce ICP, but avoid aggressive hyperventilation which causes cerebral vasoconstriction)

Sedation choice: Propofol preferred (short-acting, predictable offset, allows neurological assessment); avoid benzodiazepines (long-acting, hepatically metabolized, worsen encephalopathy).

Q2: How would you manage the hyperammonemia (185 µmol/L)? A: Ammonia greater than 150 µmol/L indicates exponential risk of cerebral edema. My strategy would be:

Immediate measures:

1. Continuous renal replacement therapy (CRRT): Most effective for ammonia clearance

   • High-volume CVVHDF (continuous venovenous hemodiafiltration)
   • Effluent flow rate 35-45 mL/kg/h
   • Target ammonia below 100-150 µmol/L

2. Therapeutic plasma exchange (TPE):

   • Removes ammonia, inflammatory cytokines, and replaces coagulation factors
   • Volume: 1-1.5 plasma volumes (typically 3-4 L)
   • May improve transplant-free survival

3. General cerebral edema prevention:

   • Head elevation 30 degrees
   • Maintain normothermia (36-37°C)
   • Euglycemia (glucose 5-10 mmol/L)
   • Maintain sodium 140-145 mmol/L (avoid hyponatremia)
   • Minimal sedation (propofol if required)

4. Avoid:

   • Lactulose (not recommended in ALF; causes bowel distension)
   • Rifaximin (insufficient evidence in ALF; too slow)

ICP monitoring: Consider if ammonia remains greater than 150-200 µmol/L despite CRRT, or if progression to grade IV.

Q3: Would you give NAC for drug-induced ALF? A: Yes. Although the landmark Lee et al. (2009) trial showed NAC improved transplant-free survival in non-paracetamol ALF (primarily DILI), the benefit was restricted to early-stage disease (grade I-II encephalopathy):

• Grade I-II: NAC 52% vs placebo 30% transplant-free survival
• Grade III-IV: NAC 9% vs placebo 22% (no benefit)

This patient has grade III encephalopathy, so NAC is unlikely to improve transplant-free survival. However:

1. Low risk: NAC is generally well-tolerated
2. Potential additional benefits: Antioxidant, anti-inflammatory, improves microvascular perfusion
3. Guideline recommendation: AASLD/EASL suggest considering NAC for all non-paracetamol ALF

I would administer NAC (150 mg/kg loading over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h) while acknowledging limited benefit at this stage.

Q4: How do you apply King's College Criteria here? A: This is non-paracetamol ALF (DILI from anti-TB medications). King's College Criteria for non-paracetamol ALF require:

INR greater than 6.5 OR any three of the following five:

1. Age below 10 or greater than 40 years: ✓ (55 years)
2. Aetiology: Non-A non-B hepatitis, halothane, or idiosyncratic drug reaction: ✓ (isoniazid DILI)
3. Jaundice to encephalopathy interval greater than 7 days: ? (need history - TB treatment started 6 weeks ago, but when did jaundice start?)
4. INR greater than 3.5: ✓ (INR 4.2)
5. Bilirubin greater than 300 µmol/L: ✓ (420 µmol/L)

Current status: Meets at least 3-4 of 5 criteria (depending on jaundice-to-encephalopathy interval), suggesting transplantation should be considered.

Additionally:

• Grade III encephalopathy
• Elevated ammonia (185 µmol/L)
• AKI developing (Cr 145 µmol/L, though below 300 µmol/L threshold)

Action: Urgent discussion with liver transplant centre for listing evaluation.

Q5: What if she has active TB? Does this affect transplant candidacy? A: Active tuberculosis is a relative contraindication to liver transplantation. Management approach:

Pre-transplant assessment:

1. Microbiology: Sputum culture, TB PCR, chest X-ray, CT chest
2. Infectious diseases consultation: Risk-benefit of transplantation with active TB
3. Alternative anti-TB regimen: Stop hepatotoxic agents (isoniazid, rifampicin, pyrazinamide); consider:
   • Ethambutol (safer)
   • Fluoroquinolones (moxifloxacin, levofloxacin)
   • Aminoglycosides (streptomycin - but nephrotoxic)

If active TB confirmed:

• May require temporary deferral of transplantation if TB is controlled
• If life-threatening ALF (King's College Criteria met), transplant may proceed with aggressive anti-TB therapy post-transplant
• Post-transplant immunosuppression increases risk of TB reactivation/dissemination

If latent TB or treated TB: Generally not a contraindication; prophylaxis post-transplant.

Q6: The ICP is 28 mmHg and CPP is 52 mmHg. What would you do? A: This patient has intracranial hypertension (ICP 28 mmHg, target below 20-25 mmHg) and borderline cerebral perfusion pressure (CPP 52 mmHg, target greater than 50-60 mmHg).

Immediate management:

1. Optimize head position: Ensure head elevation 30 degrees, neck neutral (avoid jugular venous obstruction)

2. Sedation/analgesia: Ensure adequate propofol sedation; avoid agitation/coughing (increases ICP)

3. Osmotherapy:

   • Mannitol 20%: 0.5-1 g/kg IV bolus over 15-20 minutes
     • Repeat every 4-6 hours PRN
     • Monitor serum osmolality (target 310-320 mOsmol/kg; stop if greater than 320)
     • Effective within 15-30 minutes
   • Hypertonic saline (3% or 5%): 150-250 mL bolus
     • Alternative or adjunct to mannitol
     • Safe in renal failure (this patient may have developing AKI)
     • Monitor sodium (target 145-155 mmol/L)

4. Increase CPP:

   • Current CPP = 52 mmHg
   • If MAP is low, increase noradrenaline to target MAP 80-90 mmHg (to achieve CPP greater than 60 mmHg)
   • Formula: CPP = MAP - ICP

5. Augment CRRT: If not already on high-volume CRRT, increase effluent flow rate for ammonia clearance

6. Consider second-line measures if ICP remains greater than 25 mmHg despite above:

   • Therapeutic plasma exchange (if not already performed)
   • Moderate hypothermia (32-34°C): Reduces cerebral metabolic rate, but risk of infection/coagulopathy
   • Thiopental/pentobarbital coma (last resort)

Reassess transplant candidacy:

• Sustained ICP greater than 50 mmHg or CPP below 40 mmHg despite maximal therapy = contraindication to transplant (irreversible brain injury)
• Current values (ICP 28, CPP 52) still within transplantable range, but deteriorating

---

Viva 4: Applying King's College Criteria and Transplant Decision-Making

Opening Gambit: "This is a complex case of indeterminate acute liver failure with several concerning prognostic features. While he does not definitively meet King's College Criteria for non-paracetamol ALF at this moment, he has multiple poor prognostic markers including elevated lactate (4.2 mmol/L), indeterminate aetiology (worse prognosis than known causes), and progression to grade II encephalopathy within 48 hours. I would recommend listing for transplantation given the trajectory and poor expected spontaneous survival (15-25% for indeterminate ALF), while continuing intensive monitoring and supportive care."

Anticipated Questions:

Q1: Does he meet King's College Criteria? A: Let me apply the non-paracetamol King's College Criteria:

Criterion 1: INR greater than 6.5 → No (INR 5.8, just below threshold)

Criterion 2: Any 3 of the following 5:

1. Age below 10 or greater than 40 years → No (32 years)
2. Aetiology: Non-A non-B hepatitis, halothane, idiosyncratic drug → Yes (indeterminate = non-A non-B)
3. Jaundice to encephalopathy greater than 7 days → No (jaundice 3 days ago, encephalopathy yesterday = 2 days)
4. INR greater than 3.5 → Yes (INR 5.8)
5. Bilirubin greater than 300 µmol/L → Yes (385 µmol/L)

Result: Meets 3 of 5 variables → Meets King's College Criteria for transplantation

However, the INR criterion alone (greater than 6.5) is NOT met. The "any 3 of 5" criterion IS met.

Q2: What is the significance of the elevated lactate? A: Lactate 4.2 mmol/L is a critical independent prognostic marker. The Bernal et al. (2002) study (PMID: 11867109) showed that:

• Lactate greater than 3.5 mmol/L at 4-12 hours after resuscitation predicts poor outcome (death without transplantation)
• This threshold is independent of King's College Criteria
• Lactate reflects:
  1. Impaired hepatic lactate clearance (reduced gluconeogenesis)
  2. Tissue hypoperfusion (microvascular dysfunction)
  3. Mitochondrial dysfunction (severe hepatocyte injury)

Clinical significance: Even if King's College Criteria are borderline, elevated lactate (4.2 mmol/L) after adequate resuscitation strongly suggests this patient will NOT survive without transplantation.

Q3: Why is indeterminate aetiology significant? A: Indeterminate ALF (no cause found despite full workup) accounts for 15-20% of ALF cases and has the worst prognosis:

Transplant-free survival by aetiology:

• Paracetamol: 50-60%
• Hepatitis A: 50-60%
• Drug-induced (non-paracetamol): 30-40%
• Hepatitis B: 30-40%
• Indeterminate: 15-25% (worst)

Proposed mechanisms:

1. Undiagnosed viral infections (HEV, parvovirus B19, HHV-6)
2. Occult autoimmune hepatitis (seronegative)
3. Ischemic injury not clinically apparent
4. Cryptogenic metabolic disorders

Implication: Low threshold for transplant listing in indeterminate ALF due to poor spontaneous recovery.

Q4: What additional information would help the transplant decision? A: I would gather:

1. Trend over 12-24 hours:

• Is INR rising or stabilizing? (Rising INR suggests ongoing necrosis)
• Is encephalopathy worsening? (Grade I → II → III progression indicates poor prognosis)
• Is creatinine rising? (AKI worsens outcome; Cr 178 currently, threshold 300 for King's College)
• Is lactate falling with resuscitation? (Persistent elevation greater than 3.5 mmol/L is poor prognostic sign)

2. Additional prognostic markers:

• ALFSG Prognostic Index: Uses coma grade, INR, bilirubin, phosphate
• MELD score: Increasingly used; MELD greater than 30-40 suggests poor prognosis
• Factor V level: below 20% indicates severe synthetic dysfunction
• Ammonia trend: Rising ammonia (greater than 150 µmol/L) predicts cerebral edema

3. Aetiology completion:

• Repeat autoimmune screen (ANA, ASMA, IgG, anti-LKM1)
• HSV PCR (if immunocompromised or suspicious rash)
• Pregnancy test and HELLP workup (if female)
• Repeat drug/toxin history (herbal supplements, recreational drugs)

4. Transplant candidacy assessment:

• Cardiopulmonary fitness (echocardiography, chest X-ray)
• Infection screen (blood/urine/sputum cultures)
• Psychosocial evaluation (substance use, psychiatric history, support network)
• Blood group, HLA typing, crossmatch

Q5: If he progresses to grade IV encephalopathy with fixed dilated pupils, what would you do? A: Fixed dilated pupils in grade IV encephalopathy suggest brainstem herniation from cerebral edema - this is a contraindication to liver transplantation.

Immediate assessment:

1. Pupillary examination: Size, reactivity, symmetry
2. Brainstem reflexes: Corneal, oculocephalic (doll's eyes), gag, cough
3. CT head (if coagulation corrected): Assess for:
   • Cerebral edema (effacement of sulci, loss of grey-white differentiation)
   • Midline shift
   • Brainstem compression
   • Tonsillar herniation

Prognosis:

• Fixed dilated pupils with absent brainstem reflexes = brain death or imminent brain death
• This patient is no longer a transplant candidate
• Survival effectively 0%

Management:

1. Confirm neurological devastation: CT head, clinical exam by senior intensivist ± neurologist
2. Family meeting: Discuss prognosis, transition to palliative care
3. Withdraw active treatment: If confirmed irreversible brain injury
4. Organ donation discussion: If family wishes, this patient may be a candidate for organ donation AFTER brain death declaration (heart, lungs, kidneys, corneas - but liver unsuitable)

Key principle: Early listing is critical to avoid progression to irreversible neurological injury.

---

Australian and CICM-Specific Context

Liver Transplantation in Australia and New Zealand

Major Liver Transplant Centres:

Allocation System:

• UNOS equivalent: Organ and Tissue Authority (OTA) coordinates allocation
• Urgency status: Similar to UNOS Status 1A, ALF patients receive highest priority
• Geographic priority: State-based allocation, then national sharing for urgent cases
• Blood group: ABO-compatible priority; ABO-incompatible considered for Status 1A in dire circumstances

ANZICS and CICM Guidelines

The Australian and New Zealand Intensive Care Society (ANZICS) and College of Intensive Care Medicine (CICM) emphasize:

1. Early referral: All ALF patients should be discussed with transplant centre within 24 hours of ICU admission
2. Transfer criteria: Patients meeting or approaching King's College Criteria should be transferred to transplant centre
3. ICP monitoring: Recommended for grade III-IV encephalopathy in transplant candidates; acknowledge 5-10% hemorrhage risk
4. CRRT: Preferred modality for AKI and hyperammonemia in ALF; continuous therapies better tolerated than intermittent
5. Infection surveillance: Blood, urine, and sputum cultures every 48-72 hours; fungal surveillance in high-risk patients

Remote and Rural Considerations

Challenges:

• Limited access to transplant centres (e.g., Northern Territory, rural Queensland, Tasmania)
• Transfer times may be 2-6 hours for aeromedical retrieval
• Limited access to ICP monitoring, CRRT, therapeutic plasma exchange in regional centres

Retrieval Medicine:

• CareFlight (NSW), RFDS (interstate), Ambulance Victoria Air Ambulance coordinate ICU-to-ICU transfers
• Telehealth: Early consultation with transplant hepatologist via videoconference
• Stabilization: Intubation, NAC infusion, basic cerebral edema management prior to retrieval

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples:

• Higher rates of hepatitis B (endemic in remote communities; 3-5% prevalence vs below 1% non-Indigenous)
• Alcohol-related liver disease more common (socioeconomic factors, historical trauma)
• Barriers to transplantation:
  • Geographic remoteness (Northern Territory, Cape York)
  • Cultural factors (family decision-making, connection to Country)
  • Health literacy and engagement with complex medical systems

Culturally safe care:

• Engage Aboriginal Liaison Officers early
• Family-centred decision-making (extended kinship networks)
• Discuss organ donation sensitively (cultural beliefs about body integrity)

Māori (New Zealand):

• Whakapapa (genealogy) and whānau (family) central to decision-making
• Karakia (prayer) and tikanga (cultural protocols) should be accommodated in ICU
• Lower transplant listing rates despite higher liver disease burden (access, cultural factors)

---

Special Populations and Contexts

Pregnancy-Related ALF

Causes:

1. HELLP syndrome: Hemolysis, Elevated Liver enzymes, Low Platelets (3rd trimester)
2. Acute fatty liver of pregnancy (AFLP): 3rd trimester; microvesicular steatosis
3. Hepatitis E: 15-25% mortality in pregnancy (especially 3rd trimester)
4. Budd-Chiari syndrome: Hypercoagulable state in pregnancy

Management:

• Definitive treatment: Delivery (for HELLP, AFLP)
• Timing: Expedite delivery if ALF diagnosed
• Post-delivery: Rapid improvement expected within 24-72 hours
• Transplantation: Rarely required if delivery performed promptly

Paediatric ALF

Unique causes:

• Metabolic: Wilson disease, tyrosinemia, mitochondrial disorders, Niemann-Pick disease
• Infections: Adenovirus, enterovirus, parvovirus B19
• Indeterminate: Higher proportion than adults (40-50%)

King's College Criteria less validated in children; alternative criteria used:

• Liver Injury Unit (LIU) score: INR, bilirubin, ammonia, encephalopathy grade

Post-Transplant Management Pearls (CICM Exam)

Although post-transplant care is typically hepatology/transplant surgery domain, CICM candidates should know:

Immediate post-operative (first 48-72 hours):

1. Graft function: Monitor transaminases (should fall rapidly), INR (should normalize within 24-48h), lactate (should clear)
2. Primary non-function (PNF): Failure of graft to function; requires urgent re-transplantation
3. Hepatic artery thrombosis: Presents with rapid transaminase rise, AKI; requires urgent Doppler ultrasound and re-exploration
4. Bleeding: Coagulopathy from graft dysfunction, surgical bleeding; may require re-exploration

Immunosuppression:

• Induction: Basiliximab (IL-2 receptor antagonist) or antithymocyte globulin (ATG)
• Maintenance: Tacrolimus (calcineurin inhibitor) + mycophenolate mofetil (MMF) ± corticosteroids
• Complications: Infection (CMV, PJP), nephrotoxicity (tacrolimus), hyperglycemia

Infection prophylaxis:

• CMV: Valganciclovir (if donor CMV+/recipient CMV- or high-risk)
• Pneumocystis jirovecii: Trimethoprim-sulfamethoxazole
• Fungal: Fluconazole or echinocandin in high-risk patients

---

Key Management Summary Tables

Initial Resuscitation Bundle (First 6 Hours)

Drug Dosing Adjustments in ALF

Liver Transplant Workup Checklist

Pre-listing assessment (complete within 24 hours):

Absolute contraindications:

• ☐ Multi-organ failure with no prospect of recovery
• ☐ Irreversible brain injury (fixed dilated pupils, sustained ICP greater than 50 mmHg, CPP below 40 mmHg)
• ☐ Active uncontrolled sepsis (relative if sepsis controllable)
• ☐ Severe cardiopulmonary disease incompatible with transplant surgery
• ☐ Active malignancy (except hepatocellular carcinoma within Milan criteria)
• ☐ Active substance abuse (alcohol, illicit drugs within 6 months)

Essential investigations:

• ☐ Blood group, tissue typing, crossmatch
• ☐ Virology: HIV, HBV, HCV, CMV, EBV, HSV
• ☐ Echocardiography (LV function, pulmonary hypertension)
• ☐ Chest X-ray
• ☐ Infection screen: Blood, urine, sputum cultures
• ☐ CT chest/abdomen/pelvis (if malignancy suspected)
• ☐ Pregnancy test (if female of childbearing age)
• ☐ Psychosocial assessment

Prognostic assessment:

• ☐ King's College Criteria applied
• ☐ Lactate at 4-12h post-resuscitation (below 3.5 mmol/L favourable)
• ☐ MELD score calculated
• ☐ Ammonia level (greater than 150 µmol/L high risk)
• ☐ Encephalopathy grade trend (improving vs worsening)

Comparison: ALF vs ACLF

---

Take-Home Messages for CICM Exam

1. Definition: ALF = INR ≥1.5 + any encephalopathy + below 26 weeks + no pre-existing liver disease
2. Paracetamol is #1 cause (40-50%); give NAC to ALL ALF patients (paracetamol AND non-paracetamol)
3. King's College Criteria are essential for transplant evaluation:
   • Paracetamol: pH below 7.3 OR (INR greater than 6.5 + Cr greater than 300 + grade III-IV)
   • Non-paracetamol: INR greater than 6.5 OR any 3 of 5 (age, aetiology, interval, INR, bilirubin)
4. Cerebral edema kills: Ammonia greater than 150 µmol/L = high risk; manage with CRRT, ICP monitoring (grade III-IV), osmotherapy
5. Do NOT correct INR routinely: It's a prognostic marker, NOT a bleeding risk indicator (only correct for active bleeding or procedures)
6. Infection is common (50-80%): Surveillance cultures every 48-72h; low threshold for empirical antibiotics
7. Lactate greater than 3.5 mmol/L at 4-12h post-resuscitation predicts poor outcome independent of King's College Criteria
8. Indeterminate ALF has worst prognosis (15-25% spontaneous survival) - low threshold for transplant listing
9. Contact transplant centre within 24 hours of ALF diagnosis - early listing is critical
10. Fixed dilated pupils = no transplant (irreversible brain injury)

---

References

1. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534. PMID: 24369077
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081. PMID: 28417882
3. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864. PMID: 19828176
4. Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46(6):1844-1852. PMID: 17685471
5. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445. PMID: 2490426
6. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954. PMID: 12484709
7. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41(5):1179-1197. PMID: 15841455
8. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282-298.
9. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342(8866):273-275. PMID: 8101303
10. Bernal W, Cross TJ, Auzinger G, et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol. 2009;50(2):306-313. PMID: 19070393
11. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437. PMID: 23474284
12. Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102(11):2459-2463. PMID: 17608778
13. Shakil AO, Kramer D, Mazariegos GV, et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6(2):163-169. PMID: 10719014
14. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-521. PMID: 16083708
15. Khuroo MS, Kamili S. Aetiology and prognostic factors in acute liver failure in India. J Viral Hepat. 2003;10(3):224-231. PMID: 12753341
16. Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: Summary of a workshop. Hepatology. 2008;47(4):1401-1415. PMID: 18318440
17. Farmer DG, Anselmo DM, Ghobrial RM, et al. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg. 2003;237(5):666-675. PMID: 12724632
18. Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med. 2003;31(1):299-305. PMID: 12545033
19. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364-1372. PMID: 16317692
20. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292. PMID: 18635433
21. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991;303(6809):1026-1029. PMID: 1954453
22. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557-1562. PMID: 3059186
23. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419-1425. PMID: 23419359
24. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology. 2015;148(7):1340-1352. PMID: 25754159
25. Hu J, Zhang Q, Ren X, et al. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015;39(5):594-599. PMID: 25887919
26. Schilsky ML. Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis. 2017;21(4):755-767. PMID: 28987263
27. Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology. 2008;48(4):1167-1174. PMID: 18798336
28. Rutherford A, Davern T, Hay JE, et al. Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol. 2006;4(12):1544-1549. PMID: 17162241
29. Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114(3):188-193. PMID: 12637132
30. Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. 1999;29(3):648-653. PMID: 10051463
31. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-1589. PMID: 16315300
32. Lisman T, Bakhtiari K, Adelmeijer J, et al. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost. 2012;10(7):1312-1319. PMID: 22578148
33. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44(2):440-445. PMID: 16871542
34. Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990;11(1):49-53. PMID: 2295469
35. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716-721. PMID: 11870389
36. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation in drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl. 2009;15(7):719-729. PMID: 19562710
37. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445. PMID: 2490426
38. McPhail MJ, Wendon JA, Bernal W. Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol. 2010;53(3):492-499. PMID: 20580460
39. Koch DG, Tillman H, Durkalski V, et al. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14(8):1199-1206. PMID: 27085758
40. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-563. PMID: 11867109
41. Nabi T, Nabi S, Rafiq N, Shah A. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study. Saudi J Gastroenterol. 2017;23(3):169-175. PMID: 28611343
42. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007;35(11):2498-2508. PMID: 17901832
43. Slack AJ, Auzinger G, Willars C, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 2014;34(1):42-48. PMID: 24028214
44. Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol. 2016;64(1):69-78. PMID: 26325537
45. Acharya SK, Bhatia V, Sreenivas V, et al. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology. 2009;136(7):2159-2168. PMID: 19505425
46. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-1589. PMID: 16315300
47. Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46(6):1844-1852. PMID: 17685471
48. Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med. 2009;37(7 Suppl):S258-264. PMID: 19535956
49. Bernal W, Murphy N, Brown S, et al. A multicentre randomized controlled trial of moderate hypothermia to prevent intracranial hypertension in acute liver failure. J Hepatol. 2016;65(2):273-279. PMID: 27017038
50. Karvellas CJ, Farhat MR, Sajjad I, et al. A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care. 2011;15(1):R72. PMID: 21352532
51. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360-1368. PMID: 18471513
52. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996;16(4):389-402. PMID: 9027952
53. Karvellas CJ, Pink F, McPhail M, et al. Bacteremia, acute physiology and chronic health evaluation II and modified end-stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med. 2010;38(1):121-126. PMID: 19770748
54. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125(3):755-764. PMID: 12949721
55. Plauth M, Cabré E, Riggio O, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr. 2006;25(2):285-294. PMID: 16707194
56. Farmer DG, Anselmo DM, Ghobrial RM, et al. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg. 2003;237(5):666-675. PMID: 12724632
57. Germani G, Theocharidou E, Adam R, et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol. 2012;57(2):288-296. PMID: 22521344
58. Campsen J, Zimmerman M, Trotter J, et al. Liver transplantation for acute liver failure at the University of Colorado: complications of placement and management of intracranial pressure monitors. Transplant Proc. 2008;40(10):3526-3528. PMID: 19100432
59. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr Gastroenterol Rep. 2007;9(1):66-73. PMID: 17335680